Literature DB >> 3504130

Implantable enzyme capsules for cancer chemotherapy from bakers' yeast cytosine deaminase immobilized on epoxy-acrylic resin and urethane prepolymer.

T Katsuragi1, T Sakai, K Tonomura.   

Abstract

For trial use in the local chemotherapy of cancer by a combination of cytosine deaminase (EC 3.5.4.1) and 5-fluorocytosine (J. Biotechnol., (1985), 2, 13-21), 40 U of partially purified cytosine deaminase was obtained from 500 g of commercial compressed bakers' yeast. The enzyme, which is unstable, was immobilized to stabilize it by the use of commercial epoxy-acrylic beads (Eupergit C). The immobilized enzyme was made into enzyme capsules with cellulose tubing for dialysis to encapsulate it or urethane polymer to entrap it, which materials are biocompatible. The activity of the intact cellulose capsules thus made was 0.4% that of the immobilized enzyme inside. The enzyme capsules also were stable. Ten days after the cellulose capsules were implanted in rats, 25% of the starting activity remained. When the polyurethane capsules were tested in vitro for 9 mo for thermostability at 37 degrees C, the activity decreased rapidly (with a half-life of 28 d) during the first 4 mo, and then slowly (half-life, about 100 d) during the next 5 mo. A calculation to transform the biphasic decline into a sum of the exponential decline of two components of enzymic activities with different strengths and half-lives showed that the larger half-life was 5 mo.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3504130     DOI: 10.1007/BF02798356

Source DB:  PubMed          Journal:  Appl Biochem Biotechnol        ISSN: 0273-2289            Impact factor:   2.926


  7 in total

1.  Fluorinated pyrimidines, a new class of tumour-inhibitory compounds.

Authors:  C HEIDELBERGER; N K CHAUDHURI; P DANNEBERG; D MOOREN; L GRIESBACH; R DUSCHINSKY; R J SCHNITZER; E PLEVEN; J SCHEINER
Journal:  Nature       Date:  1957-03-30       Impact factor: 49.962

2.  Procedure for the study of certain enzymes in minute amounts and its application to the investigation of cytosine deaminase.

Authors:  E CHARGAFF; J KREAM
Journal:  J Biol Chem       Date:  1948-09       Impact factor: 5.157

3.  Immobilization of Escherichia coli Cells Containing Aspartase Activity with Polyurethane and Its Application for l-Aspartic Acid Production.

Authors:  M C Fusee; W E Swann; G J Calton
Journal:  Appl Environ Microbiol       Date:  1981-10       Impact factor: 4.792

4.  Cryptococcal meningitis.

Authors:  R McDonald; E N Greenberg; R Kramer
Journal:  Arch Dis Child       Date:  1970-06       Impact factor: 3.791

5.  [tRNA's from yeast having incorporated 5-fluorouracil arising from in vivo deamination of 5-fluorocytosine].

Authors:  R Giege; J H Weil
Journal:  Bull Soc Chim Biol (Paris)       Date:  1970-03-31

6.  Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules.

Authors:  T Nishiyama; Y Kawamura; K Kawamoto; H Matsumura; N Yamamoto; T Ito; A Ohyama; T Katsuragi; T Sakai
Journal:  Cancer Res       Date:  1985-04       Impact factor: 12.701

7.  Genetic and physiological aspects of resistance to 5-fluoropyrimidines in Saccharomyces cerevisiae.

Authors:  R Jund; F Lacroute
Journal:  J Bacteriol       Date:  1970-06       Impact factor: 3.490

  7 in total
  3 in total

1.  Yeast cytosine deaminase mutants with increased thermostability impart sensitivity to 5-fluorocytosine.

Authors:  Tiffany S Stolworthy; Aaron M Korkegian; Candice L Willmon; Andressa Ardiani; Jennifer Cundiff; Barry L Stoddard; Margaret E Black
Journal:  J Mol Biol       Date:  2008-01-11       Impact factor: 5.469

2.  Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo.

Authors:  Michi Fuchita; Andressa Ardiani; Lei Zhao; Kinta Serve; Barry L Stoddard; Margaret E Black
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

Review 3.  Microbial cytosine deaminase is a programmable anticancer prodrug mediating enzyme: antibody, and gene directed enzyme prodrug therapy.

Authors:  Ashraf S A El-Sayed; Nabil Z Mohamed; Marwa A Yassin; Mahmoud M Amer; Reyad El-Sharkawy; Nesma El-Sayed; Mostafa G Ali
Journal:  Heliyon       Date:  2022-09-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.